2021
Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
HOLICKÁ, Martina; Jakub VYSLOUŽIL; Kateřina KUBOVÁ; Jan MUSELÍK; David VETCHÝ et al.Základní údaje
Originální název
Gonadoliberin (gonadotropin uvolňující hormon), jeho agonisté a antagonisté
Název anglicky
Gonadoliberin (Gonadotropin-Releasing Hormone), Its Agonists and Antagonists
Autoři
Vydání
CHEMICKÉ LISTY, Praha, CHEMICKE LISTY, 2021, 0009-2770
Další údaje
Jazyk
čeština
Typ výsledku
Článek v odborném periodiku
Obor
30104 Pharmacology and pharmacy
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 0.356
Označené pro přenos do RIV
Ano
Kód RIV
RIV/00216224:14160/21:00119761
Organizační jednotka
Farmaceutická fakulta
UT WoS
EID Scopus
Klíčová slova anglicky
GnRH analogues; GnRH agonist; GnRH antagonist; hormones; therapy
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 28. 8. 2024 11:36, Mgr. Michal Petr
V originále
Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
Anglicky
Nowadays, analogues of gonadotropin-releasing hormone are among the standard drugs in several indications, often using modern dosage forms. Globally, their market is estimated at billions of $ annually. This review article summarizes basic information on the relationship between structure and effect, pharmacology, and application of gonadotropin-releasing hormone and its synthetic analogues. Due to their properties, namely a higher efficiency and a higher binding affinity for the gonadotropinreleasing hormone receptor compared to native gonadotropin releasing hormone, the analogues have found applications in the treatment of many diseases, where it is necessary to suppress the secretion of gonadotropins and sex hormones. They are usually indicated for the treatment of cancers of various origins, premature puberty or artificial insemination. Due to their peptide nature, they are not administered orally, but require injection or intranasal administration. Compared to agonists, antagonists show faster onset of action and the absence of the so-called flareup phenomenon, i.e., temporarily increased serum levels of lutropin, follitropin and, consequently, of testosterone and estradiol.
Návaznosti
| QK1810221, projekt VaV |
|